Mariana Lombardi Peres de Carvalho
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Mariana Lombardi Peres de Carvalho has a total of 53 co-authors. Here are the top co-authors by number of shared publications:
- Luciana Sacilotto
Universidade de São Paulo
7 shared publications - José Eduardo Krieger
Instituto do Coracao (InCor), Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo
5 shared publications - Natália Quintella Sangiorgi Olivetti
Instituto do Coracao (InCor), Hospital das Clínicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Brazilian Genomic Cardiovascular Consortium, MAPA Genoma, Brazil (N.Q.S.O., L.S., J.d.B.N.F., S.F., M.P., B.M.S., M.M., P.M.S., G.N., K.V., F.A., M.L.P.d.C., E.L.M., J.S.L.P., L.V.L.P., A.N.L., A.C.P., F.d.C.D., M.S., F.F., J.E.K.).
5 shared publications - Bianca Domit Werner Linnenkamp
Universidade de São Paulo
4 shared publications - Francisco Darrieux
Universidade de São Paulo, Brasil
4 shared publications - Emanuelle Leonilia Marques
Universidade de São Paulo, Brasil
3 shared publications
Latest Publications
- 2 October 2026
- Published by Wolters Kluwer Health in Circulation: Genomic and Precision Medicine
FLNC -Related Cardiomyopathies in an Admixed Population: Expanding the Genotype-Phenotype Spectrum and Clinical Correlates
BACKGROUND: Pathogenic and likely pathogenic variants in filamin C ( FLNC ) cause a broad spectrum of cardiomyopathies. However, available genotype-phenotype data are derived predominantly from European and North American populations, with limited representation of admixed populations. METHODS: We characterized carriers of pathogenic/likely pathogenic FLNC variants identified among 2654 unrelated probands undergoing exome sequencing for suspected inherited cardiomyopathy and their relatives identified through cascade screening. Clinical, electrocardiographic, imaging, genetic, and longitudinal data were analyzed according to cardiomyopathy phenotype and variant class. Genetic ancestry was evaluated. Associations with arrhythmic, heart failure, and composite outcomes were examined in exploratory analyses. RESULTS: The cohort included 97 carriers (58 probands, 39 relatives), of whom 72 had cardiomyopathy and 25 were phenotype-negative at evaluation. Truncating variants predominated among patients with arrhythmogenic cardiomyopathy and dilated cardiomyopathy, whereas missense variants were concentrated among those with hypertrophic cardiomyopathy and restrictive cardiomyopathy. Arrhythmogenic cardiomyopathy and dilated cardiomyopathy were characterized by a greater burden of ventricular arrhythmias, low QRS voltage, systolic dysfunction, and myocardial fibrosis, whereas hypertrophic cardiomyopathy and restrictive cardiomyopathy showed greater wall thickness and more atrial arrhythmias. Twelve pathogenic/likely pathogenic variants absent from gnomAD and ClinVar were identified. Ancestry analysis confirmed heterogeneous genetic backgrounds but detected no ancestry-related differences in variant class or phenotype. In exploratory outcome analyses, nonsustained ventricular tachycardia, low QRS voltage, and late gadolinium enhancement were associated with outcomes. CONCLUSIONS: This deeply phenotyped Brazilian cohort expands the FLNC variant spectrum and supports broad genotype-phenotype associations across an admixed population. Exploratory findings suggest that markers of ventricular arrhythmia and myocardial fibrosis may complement left ventricular ejection fraction in future risk-stratification strategies, although validation in larger, independent cohorts is required.
- 2 October 2026
- Published by Wolters Kluwer Health in Circulation: Genomic and Precision Medicine
FLNC -Related Cardiomyopathies in an Admixed Population: Expanding the Genotype-Phenotype Spectrum and Clinical Correlates
BACKGROUND: Pathogenic and likely pathogenic variants in filamin C ( FLNC ) cause a broad spectrum of cardiomyopathies. However, available genotype-phenotype data are derived predominantly from European and North American populations, with limited representation of admixed populations. METHODS: We characterized carriers of pathogenic/likely pathogenic FLNC variants identified among 2654 unrelated probands undergoing exome sequencing for suspected inherited cardiomyopathy and their relatives identified through cascade screening. Clinical, electrocardiographic, imaging, genetic, and longitudinal data were analyzed according to cardiomyopathy phenotype and variant class. Genetic ancestry was evaluated. Associations with arrhythmic, heart failure, and composite outcomes were examined in exploratory analyses. RESULTS: The cohort included 97 carriers (58 probands, 39 relatives), of whom 72 had cardiomyopathy and 25 were phenotype-negative at evaluation. Truncating variants predominated among patients with arrhythmogenic cardiomyopathy and dilated cardiomyopathy, whereas missense variants were concentrated among those with hypertrophic cardiomyopathy and restrictive cardiomyopathy. Arrhythmogenic cardiomyopathy and dilated cardiomyopathy were characterized by a greater burden of ventricular arrhythmias, low QRS voltage, systolic dysfunction, and myocardial fibrosis, whereas hypertrophic cardiomyopathy and restrictive cardiomyopathy showed greater wall thickness and more atrial arrhythmias. Twelve pathogenic/likely pathogenic variants absent from gnomAD and ClinVar were identified. Ancestry analysis confirmed heterogeneous genetic backgrounds but detected no ancestry-related differences in variant class or phenotype. In exploratory outcome analyses, nonsustained ventricular tachycardia, low QRS voltage, and late gadolinium enhancement were associated with outcomes. CONCLUSIONS: This deeply phenotyped Brazilian cohort expands the FLNC variant spectrum and supports broad genotype-phenotype associations across an admixed population. Exploratory findings suggest that markers of ventricular arrhythmia and myocardial fibrosis may complement left ventricular ejection fraction in future risk-stratification strategies, although validation in larger, independent cohorts is required.
- Open Access
- 5 June 2025
- Published by Sociedade Brasileira de Cardiologia in ABC Heart Failure & Cardiomyopathy
- Vol. 5 (2)
Filamina C e Cardiomiopatias: Ligando Variantes Genéticas ao Seu Impacto Fenotípico
A Filamina C (FLNC) desempenha um papel crítico na manutenção da integridade estrutural das células musculares, particularmente dentro do sarcômero cardíaco. Variantes patogênicas no gene FLNC são cada vez mais reconhecidas como contribuintes significativos para uma gama diversificada de cardiomiopatias, incluindo cardiomiopatia dilatada (CMD), hipertrófica (CMH), arritmogênica (CMA) e restritiva (CMR). Esta revisão explora as correlações genótipo-fenótipo em cardiomiopatias relacionadas ao gene FLNC, enfatizando como o tipo e a localização das variantes genéticas influenciam a apresentação clínica. Variantes truncadas são principalmente associadas a CMD e CMA, caracterizadas por um alto risco de eventos arrítmicos e resultados graves, enquanto variantes missense frequentemente levam a CMH e CMR, com características fenotípicas únicas. A revisão também discute os padrões de herança, mecanismos moleculares e fenótipos clínicos de miopatias associadas à FLNC, destacando a necessidade de testes genéticos na estratificação e gestão de risco. Perspectivas futuras enfatizam a importância de expandir a pesquisa sobre os mecanismos subjacentes das variantes em filamina C e suas interações com outros fatores genéticos e ambientais. Essa compreensão integrada é crítica para melhorar o gerenciamento clínico de pacientes com cardiomiopatias relacionadas a FLNC.
- 5 June 2025
- Published by Sociedade Brasileira de Cardiologia in ABC Heart Failure & Cardiomyopathy
- Vol. 5 (2)
Open AccessFilamina C e Cardiomiopatias: Ligando Variantes Genéticas ao Seu Impacto Fenotípico
A Filamina C (FLNC) desempenha um papel crítico na manutenção da integridade estrutural das células musculares, particularmente dentro do sarcômero cardíaco. Variantes patogênicas no gene FLNC são cada vez mais reconhecidas como contribuintes significativos para uma gama diversificada de cardiomiopatias, incluindo cardiomiopatia dilatada (CMD), hipertrófica (CMH), arritmogênica (CMA) e restritiva (CMR). Esta revisão explora as correlações genótipo-fenótipo em cardiomiopatias relacionadas ao gene FLNC, enfatizando como o tipo e a localização das variantes genéticas influenciam a apresentação clínica. Variantes truncadas são principalmente associadas a CMD e CMA, caracterizadas por um alto risco de eventos arrítmicos e resultados graves, enquanto variantes missense frequentemente levam a CMH e CMR, com características fenotípicas únicas. A revisão também discute os padrões de herança, mecanismos moleculares e fenótipos clínicos de miopatias associadas à FLNC, destacando a necessidade de testes genéticos na estratificação e gestão de risco. Perspectivas futuras enfatizam a importância de expandir a pesquisa sobre os mecanismos subjacentes das variantes em filamina C e suas interações com outros fatores genéticos e ambientais. Essa compreensão integrada é crítica para melhorar o gerenciamento clínico de pacientes com cardiomiopatias relacionadas a FLNC.
- Open Access
- 1 May 2025
- Published by Sociedade Brasileira de Cardiologia in ABC Heart Failure & Cardiomyopathy
- Vol. 5 (2)
Filamin C and Cardiomyopathies: Linking Genetic Variants to Their Phenotypic Impact
Filamin C (FLNC) plays a critical role in maintaining the structural integrity of muscle cells, particularly within the cardiac sarcomere. Pathogenic variants in the FLNC gene are increasingly recognized as significant contributors to a diverse range of cardiomyopathies, including dilated (DCM), hypertrophic (HCM), arrhythmogenic (ACM), and restrictive cardiomyopathy (RCM). This review explores the genotype-phenotype correlations in FLNC-related cardiomyopathies, emphasizing how the type and location of genetic variants influence the clinical presentation. Truncating variants are primarily associated with DCM and [...] Abstract Filamin C (FLNC) plays a critical role in maintaining the structural integrity of muscle cells, particularly within the cardiac sarcomere. Pathogenic variants in the FLNC gene are increasingly recognized as significant contributors to a diverse range of cardiomyopathies, including dilated (DCM), hypertrophic (HCM), arrhythmogenic (ACM), and restrictive cardiomyopathy (RCM). This review explores the genotype-phenotype correlations in FLNC-related cardiomyopathies, emphasizing how the type and location of genetic variants influence the clinical presentation. Truncating variants are primarily associated with DCM and
- 1 May 2025
- Published by Sociedade Brasileira de Cardiologia in ABC Heart Failure & Cardiomyopathy
- Vol. 5 (2)
Open AccessFilamin C and Cardiomyopathies: Linking Genetic Variants to Their Phenotypic Impact
Filamin C (FLNC) plays a critical role in maintaining the structural integrity of muscle cells, particularly within the cardiac sarcomere. Pathogenic variants in the FLNC gene are increasingly recognized as significant contributors to a diverse range of cardiomyopathies, including dilated (DCM), hypertrophic (HCM), arrhythmogenic (ACM), and restrictive cardiomyopathy (RCM). This review explores the genotype-phenotype correlations in FLNC-related cardiomyopathies, emphasizing how the type and location of genetic variants influence the clinical presentation. Truncating variants are primarily associated with DCM and [...] Abstract Filamin C (FLNC) plays a critical role in maintaining the structural integrity of muscle cells, particularly within the cardiac sarcomere. Pathogenic variants in the FLNC gene are increasingly recognized as significant contributors to a diverse range of cardiomyopathies, including dilated (DCM), hypertrophic (HCM), arrhythmogenic (ACM), and restrictive cardiomyopathy (RCM). This review explores the genotype-phenotype correlations in FLNC-related cardiomyopathies, emphasizing how the type and location of genetic variants influence the clinical presentation. Truncating variants are primarily associated with DCM and
- Open Access
- 1 March 2025
- Published by Sociedade Brasileira de Cardiologia in Arquivos Brasileiros de Cardiologia
- Vol. 122 (3) , e20240444
Desvendando um Enigma Genético: Hipertrofia Assimétrica em um Receptor de Transplante Cardíaco Relacionado à Síndrome de Birt-Hogg-Dubé
Resumo Um caso de um homem de 54 anos que se submeteu a um transplante cardíaco com hipertrofia assimétrica precoce não relacionada à rejeição. A análise genética do doador revelou uma variante no gene da foliculina, associada à síndrome de Birt-Hogg-Dubé. O rastreamento da família do doador identificou uma hipertrofia similar e a mesma variante genética no pai do doador. Embora a avaliação genética dos tecidos dos doadores não seja realizada rotineiramente, ela pode ser crucial para compreender alterações não relacionadas ao procedimento do transplante e identificar carreadores de variantes patogênicas.
- 1 March 2025
- Published by Sociedade Brasileira de Cardiologia in Arquivos Brasileiros de Cardiologia
- Vol. 122 (3) , e20240444
Open AccessDesvendando um Enigma Genético: Hipertrofia Assimétrica em um Receptor de Transplante Cardíaco Relacionado à Síndrome de Birt-Hogg-Dubé
Resumo Um caso de um homem de 54 anos que se submeteu a um transplante cardíaco com hipertrofia assimétrica precoce não relacionada à rejeição. A análise genética do doador revelou uma variante no gene da foliculina, associada à síndrome de Birt-Hogg-Dubé. O rastreamento da família do doador identificou uma hipertrofia similar e a mesma variante genética no pai do doador. Embora a avaliação genética dos tecidos dos doadores não seja realizada rotineiramente, ela pode ser crucial para compreender alterações não relacionadas ao procedimento do transplante e identificar carreadores de variantes patogênicas.
- Open Access
- 1 March 2025
- Published by Sociedade Brasileira de Cardiologia in Arquivos Brasileiros de Cardiologia
- Vol. 122 (3)
Unveiling the Genetic Puzzle: Asymmetric Hypertrophy in a Heart Transplant Recipient Linked to Birt-Hogg-Dubé Syndrome
A case of a 54-year-old man who underwent a heart transplant with early asymmetric hypertrophy unrelated to rejection. Donor’s genetic analysis revealed a variant in folliculin gene, associated with Birt-Hogg-Dubé Syndrome. Screening of the donor’s family uncovered a similar hypertrophy and same genetic variant in the donor’s father. Although genetic evaluation of donors’ tissues is not routine, it can be crucial for understanding changes unrelated to the transplant procedure and identifying carriers of pathogenic variants.
- 1 March 2025
- Published by Sociedade Brasileira de Cardiologia in Arquivos Brasileiros de Cardiologia
- Vol. 122 (3)
Open AccessUnveiling the Genetic Puzzle: Asymmetric Hypertrophy in a Heart Transplant Recipient Linked to Birt-Hogg-Dubé Syndrome
A case of a 54-year-old man who underwent a heart transplant with early asymmetric hypertrophy unrelated to rejection. Donor’s genetic analysis revealed a variant in folliculin gene, associated with Birt-Hogg-Dubé Syndrome. Screening of the donor’s family uncovered a similar hypertrophy and same genetic variant in the donor’s father. Although genetic evaluation of donors’ tissues is not routine, it can be crucial for understanding changes unrelated to the transplant procedure and identifying carriers of pathogenic variants.
- Open Access
- 9 January 2024
- Published by MDPI AG in Diagnostics
- Vol. 14 (2) , 150
Enhancing Arrhythmogenic Right Ventricular Cardiomyopathy Detection and Risk Stratification: Insights from Advanced Echocardiographic Techniques
Introduction: The echocardiographic diagnosis criteria for arrhythmogenic right ventricular cardiomyopathy (ARVC) are highly specific but sensitivity is low, especially in the early stages of the disease. The role of echocardiographic strain in ARVC has not been fully elucidated, although prior studies suggest that it can improve the detection of subtle functional abnormalities. The purposes of the study were to determine whether these advanced measures of right ventricular (RV) dysfunction on echocardiogram, including RV strain, increase diagnostic value for ARVC disease detection and to evaluate the association of echocardiographic parameters with arrhythmic outcomes. Methods: The study included 28 patients from the Heart Institute of São Paulo ARVC cohort with a definite diagnosis of ARVC established according to the 2010 Task Force Criteria. All patients were submitted to ECHO’s advanced techniques including RV strain, and the parameters were compared to prior conventional visual ECHO and CMR. Results: In total, 28 patients were enrolled in order to perform ECHO’s advanced techniques. A total of 2/28 (7%) patients died due to a cardiovascular cause, 2/28 (7%) underwent heart transplantation, and 14/28 (50%) patients developed sustained ventricular arrhythmic events. Among ECHO’s parameters, RV dilatation, measured by RVDd (p = 0.018) and RVOT PSAX (p = 0.044), was significantly associated with arrhythmic outcomes. RV free wall longitudinal strain < 14.35% in absolute value was associated with arrhythmic outcomes (p = 0.033). Conclusion: Our data suggest that ECHO’s advanced techniques improve ARVC detection and that abnormal RV strain can be associated with arrhythmic risk stratification. Further studies are necessary to better demonstrate these findings and contribute to risk stratification in ARVC, in addition to other well-known risk markers.
- 9 January 2024
- Published by MDPI AG in Diagnostics
- Vol. 14 (2) , 150
Open AccessEnhancing Arrhythmogenic Right Ventricular Cardiomyopathy Detection and Risk Stratification: Insights from Advanced Echocardiographic Techniques
Introduction: The echocardiographic diagnosis criteria for arrhythmogenic right ventricular cardiomyopathy (ARVC) are highly specific but sensitivity is low, especially in the early stages of the disease. The role of echocardiographic strain in ARVC has not been fully elucidated, although prior studies suggest that it can improve the detection of subtle functional abnormalities. The purposes of the study were to determine whether these advanced measures of right ventricular (RV) dysfunction on echocardiogram, including RV strain, increase diagnostic value for ARVC disease detection and to evaluate the association of echocardiographic parameters with arrhythmic outcomes. Methods: The study included 28 patients from the Heart Institute of São Paulo ARVC cohort with a definite diagnosis of ARVC established according to the 2010 Task Force Criteria. All patients were submitted to ECHO’s advanced techniques including RV strain, and the parameters were compared to prior conventional visual ECHO and CMR. Results: In total, 28 patients were enrolled in order to perform ECHO’s advanced techniques. A total of 2/28 (7%) patients died due to a cardiovascular cause, 2/28 (7%) underwent heart transplantation, and 14/28 (50%) patients developed sustained ventricular arrhythmic events. Among ECHO’s parameters, RV dilatation, measured by RVDd (p = 0.018) and RVOT PSAX (p = 0.044), was significantly associated with arrhythmic outcomes. RV free wall longitudinal strain < 14.35% in absolute value was associated with arrhythmic outcomes (p = 0.033). Conclusion: Our data suggest that ECHO’s advanced techniques improve ARVC detection and that abnormal RV strain can be associated with arrhythmic risk stratification. Further studies are necessary to better demonstrate these findings and contribute to risk stratification in ARVC, in addition to other well-known risk markers.
- 1 February 2023
- Published by Wolters Kluwer Health in Circulation: Arrhythmia and Electrophysiology
- Vol. 16 (2) , 86-95
Clinical Features, Genetic Findings, and Risk Stratification in Arrhythmogenic Right Ventricular Cardiomyopathy: Data From a Brazilian Cohort
Background:Arrhythmogenic right ventricular cardiomyopathy (ARVC), a rare inherited disease, causes ventricular tachycardia, sudden cardiac death, and heart failure (HF). We investigated ARVC clinical features, genetic findings, natural history, and the occurrence of life-threatening arrhythmic events (LTAEs), HF death, or heart transplantation (HF-death/HTx) to identify risk factors. Methods:The clinical course of 111 consecutive patients with definite ARVC, predictors of LTAE, HF-death/HTx, and combined events were analyzed in the entire cohort and in a subgroup of 40 patients without sustained ventricular arrhythmia before diagnosis. Results:The 5-year cumulative probability of LTAE was 30% and HF-death/HTx was 10%. Predictors of HF-death/HTx were reduced right ventricle ejection fraction (HR: 0.93; P=0.010), HF symptoms (HR: 4.37; P=0.010), epsilon wave (HR: 4.99; P=0.015), and number of leads with low QRS voltage (HR: 1.28; P=0.001). Each additional lead with low QRS voltage increased the risk of HF-death/HTx by 28%. Predictors of LTAE were prior syncope (HR: 1.81; P=0.040), number of leads with T wave inversion (HR: 1.17; P=0.039), low QRS voltage (HR: 1.12; P=0.021), younger age (HR: 0.97; P=0.006), and prior ventricular arrhythmia/ventricular fibrillation (HR: 2.45; P=0.012). Each additional lead with low QRS voltage increased the risk of LTAE by 17%. In patients without ventricular arrhythmia before clinical diagnosis of ARVC, the number of leads with low QRS voltage (HR: 1.68; P=0.023) was independently associated with HF-death/HTx. Conclusions:Our study demonstrated the characteristics of a specific cohort with a high prevalence of arrhythmic burden at presentation, male predominance, younger age and HF severe outcomes. Our main results suggest that the presence and extension of low QRS voltage can be a risk predictor for HF-death/HTx in ARVC patients, regardless of the arrhythmic risk. This study can contribute to the global ARVC risk stratification, adding new insights to the international current scientific knowledge.
- 1 February 2023
- Published by Wolters Kluwer Health in Circulation: Arrhythmia and Electrophysiology
- Vol. 16 (2) , 86-95
Clinical Features, Genetic Findings, and Risk Stratification in Arrhythmogenic Right Ventricular Cardiomyopathy: Data From a Brazilian Cohort
Background:Arrhythmogenic right ventricular cardiomyopathy (ARVC), a rare inherited disease, causes ventricular tachycardia, sudden cardiac death, and heart failure (HF). We investigated ARVC clinical features, genetic findings, natural history, and the occurrence of life-threatening arrhythmic events (LTAEs), HF death, or heart transplantation (HF-death/HTx) to identify risk factors. Methods:The clinical course of 111 consecutive patients with definite ARVC, predictors of LTAE, HF-death/HTx, and combined events were analyzed in the entire cohort and in a subgroup of 40 patients without sustained ventricular arrhythmia before diagnosis. Results:The 5-year cumulative probability of LTAE was 30% and HF-death/HTx was 10%. Predictors of HF-death/HTx were reduced right ventricle ejection fraction (HR: 0.93; P=0.010), HF symptoms (HR: 4.37; P=0.010), epsilon wave (HR: 4.99; P=0.015), and number of leads with low QRS voltage (HR: 1.28; P=0.001). Each additional lead with low QRS voltage increased the risk of HF-death/HTx by 28%. Predictors of LTAE were prior syncope (HR: 1.81; P=0.040), number of leads with T wave inversion (HR: 1.17; P=0.039), low QRS voltage (HR: 1.12; P=0.021), younger age (HR: 0.97; P=0.006), and prior ventricular arrhythmia/ventricular fibrillation (HR: 2.45; P=0.012). Each additional lead with low QRS voltage increased the risk of LTAE by 17%. In patients without ventricular arrhythmia before clinical diagnosis of ARVC, the number of leads with low QRS voltage (HR: 1.68; P=0.023) was independently associated with HF-death/HTx. Conclusions:Our study demonstrated the characteristics of a specific cohort with a high prevalence of arrhythmic burden at presentation, male predominance, younger age and HF severe outcomes. Our main results suggest that the presence and extension of low QRS voltage can be a risk predictor for HF-death/HTx in ARVC patients, regardless of the arrhythmic risk. This study can contribute to the global ARVC risk stratification, adding new insights to the international current scientific knowledge.
- Open Access
- 4 May 2022
- Published by Sociedade Brasileira de Cardiologia in Arquivos Brasileiros de Cardiologia
- Vol. 118 (5) , 989-991
Mexiletina em um Recém-Nascido com Síndrome do QT Longo Tipo 3: Quando o Acesso se Impõe à Urgência
Introdução A síndrome do QT longo tipo 3 (SQTL3) é uma canalopatia de alta letalidade. Está associada ao déficit de fechamento dos canais tardios de sódio, decorrentes de mutações no gene SCN5A , de padrão autossômico dominante, responsável por 7-10% de todas as síndromes do QT longo (SQTL). A apresentação inicial pode ter amplo espectro, desde assintomáticos, até morte súbita no primeiro ano de vida. A adição do bloqueador do canal de sódio classe IB (mexiletina) ao propranolol ou nadolol [...] Introdução A síndrome do QT longo tipo 3 (SQTL3) é uma canalopatia de alta letalidade. Está associada ao déficit de fechamento dos canais tardios de sódio, decorrentes de mutações no gene SCN5A , de padrão autossômico dominante, responsável por 7-10% de todas as síndromes do QT longo (SQTL). A apresentação inicial pode ter amplo espectro, desde assintomáticos, até morte súbita no primeiro ano de vida. A adição do bloqueador do canal de sódio classe IB (mexiletina) ao propranolol ou nadolol
- 4 May 2022
- Published by Sociedade Brasileira de Cardiologia in Arquivos Brasileiros de Cardiologia
- Vol. 118 (5) , 989-991
Open AccessMexiletina em um Recém-Nascido com Síndrome do QT Longo Tipo 3: Quando o Acesso se Impõe à Urgência
Introdução A síndrome do QT longo tipo 3 (SQTL3) é uma canalopatia de alta letalidade. Está associada ao déficit de fechamento dos canais tardios de sódio, decorrentes de mutações no gene SCN5A , de padrão autossômico dominante, responsável por 7-10% de todas as síndromes do QT longo (SQTL). A apresentação inicial pode ter amplo espectro, desde assintomáticos, até morte súbita no primeiro ano de vida. A adição do bloqueador do canal de sódio classe IB (mexiletina) ao propranolol ou nadolol [...] Introdução A síndrome do QT longo tipo 3 (SQTL3) é uma canalopatia de alta letalidade. Está associada ao déficit de fechamento dos canais tardios de sódio, decorrentes de mutações no gene SCN5A , de padrão autossômico dominante, responsável por 7-10% de todas as síndromes do QT longo (SQTL). A apresentação inicial pode ter amplo espectro, desde assintomáticos, até morte súbita no primeiro ano de vida. A adição do bloqueador do canal de sódio classe IB (mexiletina) ao propranolol ou nadolol